The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta …
J Zhang, Q Song, L Cai, Y Xie, Y Chen - Journal of cancer research and …, 2020 - Springer
Purpose To evaluate the efficacy of 177 Lu-DOTA0-Tyr3-octreotate (177 Lu-DOTATATE)
radionuclide therapy in patients with inoperable or metastatic neuroendocrine tumours …
radionuclide therapy in patients with inoperable or metastatic neuroendocrine tumours …
Therapy With 177Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors
AT Kendi, TR Halfdanarson, A Packard… - American Journal of …, 2019 - Am Roentgen Ray Soc
OBJECTIVE. The purpose of this article is to enhance knowledge of the clinical
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
implementation of peptide receptor radionuclide therapy (PRRT) and its impact on care of …
Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline
J Del Rivero, K Perez, EB Kennedy… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1
(G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) …
(G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) …
mTOR pathway in gastroenteropancreatic neuroendocrine tumor (GEP-NETs)
S Zanini, S Renzi, F Giovinazzo… - Frontiers in …, 2020 - frontiersin.org
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) originate from
neuroendocrine cells in the gastrointestinal tract. They are heterogeneous, and though …
neuroendocrine cells in the gastrointestinal tract. They are heterogeneous, and though …
177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis
S Satapathy, BR Mittal - Nuclear medicine communications, 2019 - journals.lww.com
Objective Advanced pancreatic neuroendocrine tumors (pNETs) present a therapeutic
challenge with targeted therapies like Everolimus and 177 Lu-DOTATATE peptide receptor …
challenge with targeted therapies like Everolimus and 177 Lu-DOTATATE peptide receptor …
[HTML][HTML] Insulinoma
F Zhuo, C Anastasopoulou - 2019 - europepmc.org
Objectives: Describe the typical presenting symptoms of insulinoma. Review the evaluation
of insulinoma, including appropriate biochemical tests and localization modalities …
of insulinoma, including appropriate biochemical tests and localization modalities …
177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 …
PURPOSE To compare the efficacy and safety of 177Lu-DOTATATE plus radiosensitizing
capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in …
capecitabine and octreotide long-acting release (LAR) as first-line systemic therapy in …
Systemic treatment selection for patients with advanced pancreatic neuroendocrine tumours (PanNETs)
VG Megdanova-Chipeva, A Lamarca, A Backen… - Cancers, 2020 - mdpi.com
Pancreatic neuroendocrine tumours (PanNETs) are rare diseases and a good example of
how research is not only feasible, but also of crucial importance in the scenario of rare …
how research is not only feasible, but also of crucial importance in the scenario of rare …
Treatment of advanced gastro-entero-pancreatic neuro-endocrine tumors: a systematic review and network meta-analysis of phase III randomized controlled trials
C Ricci, G Lamberti, C Ingaldi, C Mosconi, N Pagano… - Cancers, 2021 - mdpi.com
Simple Summary The most effective and safest approach for the treatment of advanced
gastro-entero-pancreatic neuroendocrine neoplasms (GEP–NENs) remains unknown. A …
gastro-entero-pancreatic neuroendocrine neoplasms (GEP–NENs) remains unknown. A …
Predictive factors for resistant disease with Medical/Radiologic/Liver-directed anti-tumor treatments in patients with advanced pancreatic neuroendocrine neoplasms …
L Lee, I Ramos-Alvarez, RT Jensen - Cancers, 2022 - mdpi.com
Simple Summary Tumor resistance, both primary and acquired, is leading to increased
complexity in the nonsurgical treatment of patients with advanced panNENs, which would be …
complexity in the nonsurgical treatment of patients with advanced panNENs, which would be …